ClinicalTrials.gg
RecruitingNCT07047456Updated Dec 23, 2025

Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBT

A Phase 3 interventional study of Time of umbilical cord blood infusion in Acute Graft Versus Host Disease, sponsored by Anhui Provincial Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Anhui Provincial Hospital · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
134
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Graft vs Host Disease with a site in China — 38 open to participants now, 43 under way, 8 of them phase 3. Graft vs Host Disease · China.

Planned enrollment
21st of 72
134 · median 53
Started
2025
with 16 others
Phase 3
12 of 81
7 open now
Primary completion
2026-12
later than 16 of 42 live
Registered
64th of 81
by date
Lead sponsor
4 of 81
Anhui Provincial Hospital

Among the 81 studies in Graft vs Host Disease with a site in China, this one is the 21st largest by planned enrollment of the 72 interventional ones that give a count, is one of 17 that started in 2025, is one of 12 in phase 3, reaches primary completion later than 16 of the 42 other live ones, and was the 64th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 147 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

38 of the 81 studies in Graft vs Host Disease with a site in China are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 101 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 40 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Graft vs Host Disease with a site in China, or all of them as a file.
02

Study summary

To observe the effect of stem cell infusion on the development of acute graft- versus-host disease (aGVHD) in patients with malignant hematologic diseases after single-unit unrelated cord blood transplantation (sUCBT).

Read the detailed description

Acute graft-versus-host disease (aGVHD) is a major complication and cause of non-relapse mortality following allogeneic hematopoietic stem cell transplantation (allo-HSCT). The human circadian clock utilizes recurring environmental cues such as light exposure and food intake to establish 24-hour rhythmic variations in sleep, hormone secretion, metabolism, body temperature, and immune function. Current clinical strategies for aGVHD prevention primarily focus on pharmacological or immunomodulatory suppression of donor lymphocyte activity, often overlooking the impact of recipient physiological fluctuations on graft outcomes. Our preliminary studies revealed that the timing of stem cell infusion significantly influences the incidence and severity of aGVHD after sUCBT. Given the lack of prospective clinical trial data internationally regarding the effect of infusion timing on aGVHD development post-allo-HSCT, coupled with potential confounding factors in existing retrospective studies and pilot experiments, this study proposes to randomize patients based on umbilical cord blood infusion timing. The investigation will evaluate how infusion time affects aGVHD incidence, other transplantation-related complications, and long-term survival rates in hematologic malignancy patients undergoing sUCBT.

03

Conditions studied

  • Acute Graft Versus Host Disease

Browse trials for

Keywords

  • Time of umbilical cord blood infusion
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Definite diagnosis of malignant hematologic disease before transplantation, age, gender and race are not limited;
  • Participants were required to have achieved complete remission with negative minimal residual disease (MRD) prior to transplantation;
  • Participants who are proposed to receive sUCBT for the first time;
  • (ECOG) score 0-2;
  • No serious organ failure and active infection;
  • Voluntary open randomized controlled study to observe whether the time of stem cell infusion affects the occurrence of aGVHD after transplantation;
  • Each subject must sign an form (ICF) indicating that he/ she understands the purpose and procedures of the study and is willing to participate in the study; in view of the subject's condition, if the participant's own signature is not conducive to the treatment of his/her condition, the ICF will be signed by the legal representative.

Exclusion criteria

Exclusion Criteria:

  • Those with severe organ dysfunction or disease, such as severe disease and dysfunction of the heart, liver, kidneys and pancreas;
  • Any life-threatening disease, physical condition, or organ system dysfunction that, in the opinion of the investigator, may compromise participant safety and put the results of the study at unnecessary risk; drug-dependent individuals; participants with uncontrolled psychiatric disorders; and individuals with cognitive dysfunction;
  • Participants in other clinical studies that may affect aGVHD within 3 months;
  • Those whom the investigator considers unsuitable for enrollment (e.g., those who anticipate that patients will not be able to adhere to the examination and treatment due to financial and other issues).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
134 participants (estimated)

Study arms

  • Active comparator
    the early infused group

    infused umbilical cord blood within 8 am and 9 am

    Procedure: Time of umbilical cord blood infusion

  • Sham comparator
    the late infused group

    infused umbilical cord blood within 11:30 am and 12:30 pm

    Procedure: Time of umbilical cord blood infusion

Interventions

  • ProcedureTime of umbilical cord blood infusion

    Randomization of patients according to the time of umbilical cord blood infusion

06

What researchers measure

Primary outcomes

  1. The incidence of grade III to IV aGVHD

    The primary endpoint of the study will be the development of aGVHD in the first 100 days post-transplant. Acute GVHD was graded according to the Mount Sinai Acute GVHD International Consortium criteria.

    Time frame: 100 days post transplantation

Secondary outcomes

  1. The incidence of grade II to IV aGVHD

    The cumulative incidence of grade II to IV aGVHD in the first 100 days post-transplant. aGVHD was graded according to the Mount Sinai Acute GVHD International Consortium criteria.

    Time frame: 100 days post transplantation

  2. The cumulative incidence of neutrophil engraftment at 42 days after transplantation

    neutrophil engraftment time was defined as the first of three consecutive days during which the neutrophil count was at least 0.5×10\^9/L.

    Time frame: 42 days post transplantation

  3. The cumulative incidence of platelet engraftment at 60 days after transplantation

    Platelet engraftment is defined as independence from platelet transfusion for at least 7 days with a platelet count of more than ≥ 20 × 10\^9/L.

    Time frame: 60 days post transplantation

  4. The cumulative incidence of transplant-related mortality at 360 days after transplantation

    The cumulative incidence of transplant-related mortality at 360 days after transplantation

    Time frame: 360 days post transplantation

  5. The cumulative incidence of relapse at 360 days after transplantation

    The cumulative incidence of relapse at 360 days after transplantation

    Time frame: 360 days post transplantation

  6. The cumulative incidence of overall chronic GVHD at 360 days after transplantation

    The severity of chronic GVHD was graded according to the 2014 NIH criteria.

    Time frame: 360 days post transplantation

  7. The probability of GVHD-free, relapse-free survival(GRFS)

    The composite endpoint of GRFS was defined as the first events occurring after transplantation among Grade III to IV aGVHD, moderate to severe cGVHD, relapse, or death for any reason.

    Time frame: 360 days post transplantation

  8. The probability of disease-free survival(DFS)

    The DFS was defined as the interval between transplantation and disease recurrence, death or the last follow-up date, whichever occurred first.

    Time frame: 360 days post transplantation

  9. The probability of overall survival(OS)

    The OS was determined to be the time from the first day of transplantation until death from any cause or the last follow-up date.

    Time frame: 360 days post transplantation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 31 phase 3 interventional studies under Graft vs Host Disease, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 48. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2025
First posted
Jul 2, 2025
StartActual
Jul 11, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07047456
Responsible party
Sponsor
First posted
Jul 2, 2025
Start date
Jul 11, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Dec 23, 2025

Study contacts

Xiaoyu Zhu, Ph.D
Contact
xiaoyuz@ustc.edu.cn
15255456091
Yue Wu, Ph.D
Contact
ayxswy@mail.ustc.edu.cn
13805601119
Xiaoyu Zhu, Ph.D
principal investigator · The First Affiliated Hospital of University of Science and Technology of China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion